Mallinckrodt Plc Revenue Growth Rates (MNKKQ), Current and Historic Growth - CSIMarket
CSIMarket
 


Mallinckrodt Plc  (MNKKQ)
 

MNKKQ's Revenue Growth by Quarter and Year

Mallinckrodt Plc's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MNKKQ/growth
https://api.csimarket.com/api/v1/companies/MNKKQ/fundamentals
https://api.csimarket.com/api/v1/companies/MNKKQ/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
MNKKQ Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 549.50
2nd Quarter June 517.20
1st Quarter March 485.10
FY 1,551.80

MNKKQs Annual Revenue
Mallinckrodt Plc's Revenue in the fiscal year 2024 $ 1,083.40 millions
Mallinckrodt Plc's Revenue in the fiscal year 2021 $ 2,208.80 millions
Mallinckrodt Plc's Revenue in the fiscal year 2020 $ 2,213.40 millions
Mallinckrodt Plc's Revenue in the fiscal year 2019 $ 3,162.50 millions
Mallinckrodt Plc's Revenue in the fiscal year 2018 $ 3,215.60 millions




MNKKQ Revenue third quarter 2022 Y/Y Growth Comment
Mallinckrodt Plc achieved in the third quarter 2022, above Company average Revenue rise of 43.21% year on year, to $ 549.50 millions.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Revenue growth. While Mallinckrodt Plc' s Revenue jump of 43.21% ranks overall at the positon no. 2046 in the third quarter 2022.




MNKKQ Revenue ( Y/Y Growth %) 2022
FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 43.21 %
2nd Quarter June 5.36 %
1st Quarter March -18.77 %
FY   -

Financial Statements
Mallinckrodt Plc's third quarter 2022 Revenue $ 549.50 millions MNKKQ's Income Statement
Mallinckrodt Plc's third quarter 2021 Revenue $ 383.70 millions Quarterly MNKKQ's Income Statement


MNKKQ Revenue (Quarter on Quarter Growth %)

2022
FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 6.25 %
2nd Quarter June 6.62 %
1st Quarter March -1.42 %
FY (Year on Year)   -




Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #107
Healthcare Sector #304
Overall #2046

Revenue Y/Y Growth Statistics
High Average Low
61.93 % 3.25 % -37.37 %
(Dec 27 2013)   (Sep 25 2020)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #107
Healthcare Sector #304
Overall #2046
Revenue Y/Y Growth Statistics
High Average Low
61.93 % 3.25 % -37.37 %
(Dec 27 2013)   (Sep 25 2020)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Mallinckrodt Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
319.4 % 10.67 % -74.99 %
(Sep 25 2020)  


MNKKQ's III. Quarter Q/Q Revenue Comment
Mallinckrodt Plc achieved in the III. Quarter 2022 below company average Revenue increase of 6.25% quarter on quarter, to $ 549.50 millions.

Although the III. Quarter 2022 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -21.84% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Revenue quarter on quarter growth. While Mallinckrodt Plc's Revenue growth quarter on quarter, overall rank is 1424.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #112
Healthcare Sector #251
Overall #1424
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #112
Healthcare Sector #251
Overall #1424
Revenue Q/Q Growth Statistics
High Average Low
319.4 % 10.67 % -74.99 %
(Sep 25 2020)  


MNKKQ's III. Quarter Q/Q Revenue Comment
Mallinckrodt Plc achieved in the III. Quarter 2022 below company average Revenue increase of 6.25% quarter on quarter, to $ 549.50 millions.

III. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -21.84% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Revenue quarter on quarter growth. While Mallinckrodt Plc's Revenue growth quarter on quarter, overall rank is 1424.


Mallinckrodt Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 16 2022)
12 Months Ending (Apr 01 2022) 12 Months Ending (Dec 31 2021) 12 Months Ending (Sep 24 2021) 12 Months Ending (Jun 25 2021)
Cumulative Revenue 12 Months Ending $ 1,979.00
Y / Y Revenue Growth (TTM) -20.38 %
Year on Year Revenue Growth Overall Ranking # 3129
Seqeuential Revenue Change (TTM) -7.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 2046


Cumulative Revenue growth Comment
For the 12 months ended Jun 16 2022 Mallinckrodt Plc reported a fall in Revenue by -20.38% year on year, to $1,979 millions, compare to the 1.71% growth at Apr 01 2022.

In the Healthcare sector 441 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3129, from total ranking in previous quarter at 3493.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 442
Overall # 3129

Revenue TTM Y/Y Growth Statistics
High Average Low
61.93 %
3.25 %
-37.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 304
S&P 500 # 2046
Cumulative Revenue growth Comment
For the 12 months ended Jun 16 2022 Mallinckrodt Plc reported a fall in Revenue by -20.38% year on year, to $1,979 millions, compare to the 1.71% growth at Apr 01 2022.

In the Healthcare sector 441 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3129, from total ranking in previous quarter at 3493.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 442
Overall # 3129

Revenue TTM Y/Y Growth Statistics
High Average Low
61.93 %
3.25 %
-37.37 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 304
S&P 500 # 2046




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MNKKQ's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions


About Mallinckrodt Plc Revenue Growth Rates (MNKKQ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Keenova Therapeutics Plc (CIK 1567892).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-072839
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Keenova Therapeutics Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.